# The Efficacy and Safety of Ketotifen in Primary PCI Patients With STEMI

> **NCT05511831** · PHASE4 · UNKNOWN · sponsor: **Peking University Third Hospital** · enrollment: 60 (estimated)

## Conditions studied

- ST-segment Elevation Myocardial Infarction (STEMI)

## Interventions

- **DRUG:** Ketotifen Fumarate
- **DRUG:** standard treatment

## Key facts

- **NCT ID:** NCT05511831
- **Lead sponsor:** Peking University Third Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05511831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05511831, "The Efficacy and Safety of Ketotifen in Primary PCI Patients With STEMI". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05511831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*